| Literature DB >> 20188526 |
Leonard Amaral1, Martin J Boeree, Stephen H Gillespie, Zarir F Udwadia, Dick van Soolingen.
Abstract
Thioridazine (TDZ) has been shown to have in vitro activity against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis, to promote the killing of intracellular MDR and XDR strains and to cure the mouse of antibiotic-susceptible and -resistant pulmonary tuberculosis (TB) infections. Recently, TDZ was used to cure 10 of 12 XDR-TB patients in Buenos Aires, Argentina. At the time of writing, it is being used for the therapy of non-antibiotic-responsive terminal XDR-TB patients in Mumbai, India, on the basis of compassionate therapy and although it is too early to determine a cure, the patients have improved appetite, weight gain, are afebrile and free of night sweats, and their radiological picture shows great improvement. Because XDR-TB is essentially a terminal disease in many areas of the world and no new effective agents have yet to yield successful clinical trials, global clinical trials for the therapy of XDR-TB are urgently required. 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20188526 DOI： 10.1016/j.ijantimicag.2009.12.019
Source DB: PubMed Journal: Int J Antimicrob Agents ISSN： 0924-8579 Impact factor: 5.283